CHEK1 and neoplasm: In vitro and in vivo (on patient-derived xenograft mice models) studies revealed an extensive activity of the other potent CHEK1 (and CHEK2) inhibitor prexasertib in HGSOC, both as a monotherapy and in combination with PARPi olaparib, with anti-tumor activity even in olaparib-resistant models [204].